Cervical cancer screening: Less testing, smarter testing

ABSTRACT

In its 2009 recommendations for cervical cancer screening, the American College of Obstetricians and Gynecologists (ACOG) calls for less-frequent but smarter screening that integrates testing for human papillomavirus (HPV) infection with the Papanicolaou (Pap) test. We review the recommendations from this and other organizations and how and why they are evolving.

KEY POINTS

Persistent infection with one of the 18 high-risk types of HPV is associated with the development of nearly all cases of cervical cancer.

The 2009 ACOG guidelines recommend starting to screen with the Pap test at an older age (21 years) than in the past, and they recommend a longer screening interval for women in their 20s, ie, every 2 years instead of yearly.

Women age 30 and older should undergo both Pap and HPV testing. If both tests are negative, screening should be done again no sooner than 3 years. Alternatively, women age 30 or older who have had three consecutive negative Pap tests can be screened by Pap testing every 3 years.

Although vaccination can prevent most primary infections with high-risk HPV, it does not eliminate the need for continuing cervical cancer screening, as it does not protect against all high-risk HPV subtypes.

Screening can stop at age 65 to 70 in women who have had three negative Pap tests in a row and no abnormal tests within the past 10 years.

doi:10.3949/ccjm.78a.11033
death from cancer in women worldwide. According to a recent estimate, there are almost 500,000 new cases and 240,000 deaths from this disease worldwide every year.4 If effective global screening programs could be set up, they would markedly reduce the incidence of cervical cancer and deaths from it.5

HPV IS NECESSARY BUT NOT SUFFICIENT FOR CERVICAL CANCER TO DEVELOP

For cervical cancer to develop, the essential first step is infection of the cervical epithelium with one of the oncogenic (high-risk) types of HPV (see below).6–10 Walboomers et al9 tested cervical tissue samples taken from 932 women with cervical cancer and detected HPV DNA in 930 (99.8%) of them.

Fortunately, most HPV-infected women do not develop cervical cancer, as most young women clear the infection in an average of 8 to 24 months.11,12 However, if the infection persists, and if it is one of the high-risk types of HPV, precursor lesions can develop that can progress to cervical cancer.13 The evidence conclusively supports the association between oncogenic HPV infection and the subsequent development of virtually all cases of cervical cancer.6–10

Known risk factors for HPV persistence and the subsequent development of high-grade lesions are cigarette smoking and a compromised immune system.14,15

Terminology: Results of Pap smears
• Normal
• Atypical squamous cells of undetermined significance (ASC-US)
• Low-grade squamous intraepithelial lesions (LSIL)
• High-grade squamous intraepithelial lesions (HSIL)
• Cancer.

Terminology: Results of cervical biopsy
• Normal
• Cervical intraepithelial neoplasia grade 1 (CIN1)
• CIN2 (previously called moderate dysplasia)
• CIN3 (previously called severe dysplasia)
• Carcinoma in situ

• Invasive cervical cancer.

Lesions that are CIN2 or higher are considered high-grade.13

The 18 high-risk HPV types

More than 40 types of HPV infect the genital tract16; 18 of these (types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82) are classified as high-risk because of their causative association with cervical cancer (ie, their oncogenic potential).17

How HPV causes cervical cancer

Basic science research has provided insight into how high-risk HPV causes cervical cancer (FIGURE 1).

In laboratory cultures, normal human cells die out after a few generations. However, if human epithelial cells are infected by one of the high-risk types of HPV, they can go on dividing indefinitely.18,19

Two HPV proteins, E6 and E7, induce this cell “immortalization.”20,21 E6 from high-risk HPV binds to the human tumor-suppressor protein p53 and rapidly degrades it in a proteolytic process. The p53 protein normally suppresses cell proliferation by arresting growth in the G1 phase of the cell cycle. Therefore, with less p53, the cell cannot suppress uncontrolled cell growth.22–24

Similarly, E7 from high-risk HPV forms a complex with another human tumor suppressor, the retinoblastoma protein (pRB), and disrupts its binding to a transcriptional factor, E2F-1. The freed E2F-1 then stimulates DNA synthesis and uncontrolled cell growth.25

Furthermore, HPV-16 E6 and E7 proteins can collectively cause cellular genetic instability.26

The carcinogenic mechanism of high-risk HPV is complex. The host immune system and natural tumor suppression play important roles. However, the natural history of cervical intraepithelial neoplasia is not well understood. For example, it remains unclear if low-grade lesions such as CIN1 are necessary precursors to high-grade lesions and invasive cancer.6,7,10

THE PAP TEST: SPECIFIC BUT NOT VERY SENSITIVE, AND PRONE TO ERROR

The principal advantage of cervical cytologic testing (ie, the Pap test) in detecting cervical
Human papillomavirus in cervical cancer

Persistent infection with high-risk types of human papillomavirus (HPV) is responsible for nearly all cases of cervical squamous carcinoma. HPV testing is more sensitive than cervical cytology for detecting precancerous cervical lesions.

Precancerous lesions of the cervix—ranging from low-grade dysplasia (cervical intraepithelial neoplasia grade 1 [CIN1]) to moderate dysplasia (CIN2) to severe dysplasia (CIN3)—can lead to the development of invasive cervical cancer.
dysplasia is its overall high specificity. Many studies have found that the specificity of conventional Pap testing can reach approximately 98%.27

However, the conventional Pap test has drawbacks. Contaminants such as blood, discharge, and lubricant can make it difficult to interpret, and artifact can occur with air-drying of the Pap smear as it is transferred to the cell slide (“air-drying artifact”).

**Liquid-based cytologic study has replaced the older method**

To overcome these disadvantages, a liquid-based method of cervical cytologic study, ThinPrep (Hologic, Bedford, MA), was introduced in the mid-1990s. In this method, cell samples are first transferred to a liquid solution for mechanical separation from contaminants, and a representative sample of cells is then placed on a slide for review.

The liquid-based method filters out most contaminating blood, inflammatory cells, and debris. It also eliminates the air-drying artifact in the conventional Pap collection technique and improves specimen adequacy. Cytotechnologists find liquid-based specimens easier to read because the cells are more evenly distributed on a clearer background. Another advantage is that we can routinely test for HPV in the available residual specimen if the cytologic interpretation is abnormal.

The main disadvantages of the liquid-based method are that its specificity is lower than that of conventional Pap smears (around 78%) and that it costs more.28 Nevertheless, the liquid-based technique has become the main method of cervical cytology, used by nearly 90% of gynecologists in the United States since 2003.1

**Cytology is still prone to false-negative results**

Despite the success of both conventional Pap testing and liquid-based Pap testing, cervical cytology is inherently prone to sample-quality variation, subjective interpretation error, and false-negative results. False-negative results can be due to failure to transfer dysplastic cells to the slide or failure of the cytologist to recognize abnormal cells. In 30% of new cases of cervical cancer, the patient had recently had a Pap test that was interpreted as negative.1,29

Errors in interpretation are exacerbated by inconsistency among cytopathologists. In one study,6,30 when a group of quality-control pathologists reviewed nearly 5,000 cytology specimens, they came to the same conclusion that the original reviewers did more than 50% of the time only for negative and LSIL readings. Of the specimens initially reported as ASC-US, almost 40% were reclassified as negative on further review. Of those originally interpreted as HSIL, more than 50% were reclassified as LSIL, as ASC-US, or as negative.

Furthermore, many studies found that the sensitivity of conventional Pap testing was only around 50%.27 The new liquid-based Pap test uses computer imaging, which has improved the rate of detection of cervical dysplasia but may still miss 15% to 35% of cases of HSIL (severe dysplasia) or cancer.31 Failure to detect cervical dysplasia or cancer on Pap smear has led to a number of lawsuits.32

Clearly, with its relatively low sensitivity, cervical cytology is no longer good enough to use as a sole screening test in all situations. However, its high specificity is an advantage when it is combined with HPV testing in screening.

**HPV TESTING AND PAP TESTING COMPLEMENT EACH OTHER**

From 17% to 36% of HPV-infected women develop a cytologic abnormality within 5 years, compared with 4% to 15% of women who are HPV-negative.33,34 The usefulness of testing for HPV in women who have had an abnormal Pap test has been well demonstrated in multiple studies.35–38

The landmark Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS)39 found that 82.9% of women with LSIL were HPV-positive. The investigators concluded that HPV testing has little utility in women with LSIL, as the test would likely be positive and thus would not change the decision to perform colposcopy.

However, in women with ASC-US, the sensitivity of HPV testing for predicting CIN3 or cancer was 96.3% and the negative predic-
tive value was 99.5%. In contrast, the sensitivity of a single repeat Pap test was only 44.1%. This large randomized trial conclusively validates the important role of HPV testing in triaging women with ASC-US.

More recently, a meta-analysis of 20 studies of HPV testing in women with ASC-US found that it had a sensitivity of 92.5% and a specificity of 62.5% for detecting CIN2 or worse lesions, and a sensitivity of 95.6% and a specificity of 59.2% for detecting CIN3 or worse lesions.40

Furthermore, HPV testing in primary cervical cancer screening is strongly supported by large cross-sectional studies41–45 and randomized clinical trials.46,47 These studies have conclusively shown that HPV testing is significantly more sensitive than Pap testing for detecting cervical intraepithelial neoplasia, and that, when combined with Pap testing, it can achieve nearly 100% clinical sensitivity and nearly 93% specificity in women age 30 or older. Women who have negative results on both the HPV test and the Pap test can be reassured that their risk of undetected CIN2, CIN3, or cervical cancer is extremely low, since HPV testing has a negative predictive value close to 100%.46

In large multinational European studies involving more than 24,000 women, the risk of CIN3 or cancer after 6 years of follow-up was only 0.28% in women who had negative results on both HPV and Pap testing at baseline. This rate was basically the same as in women who tested negative for HPV alone (0.27%). However, it was significantly lower than that of all women who had negative Pap test results (0.97%). The combination of HPV testing and Pap testing at 6-year intervals offered better protection than Pap testing alone at 3-year intervals.48

**NEW STANDARD OF CARE: THE LATEST SCREENING GUIDELINES**

Until the mid-1990s, the strategy for cervical cancer screening had remained largely unchanged for many years. Since then, several advances have prompted changes in the standard of care.

1996—The US Food and Drug Administration (FDA) approved liquid-based Thin-Prep for cervical cancer screening, which improved specimen adequacy and reduced ambiguous interpretations compared with the original slide-based method of collection.49

2001—The Bethesda terminology for reporting cervical cytology results was updated. First proposed in 1988 to replace the original Papanicolaou system and revised in 1991, this standardized terminology enabled better clinical decision-making.50

2001—The FDA approved HPV testing for women with ASC-US. This provided a better triage strategy for deciding which women need colposcopy to exclude true intraepithelial lesions. Following the FDA approval, the clinical effectiveness of HPV testing in women with ASC-US was validated by a large randomized clinical trial—the ALTS.51

2003—The FDA approved HPV testing in conjunction with Pap testing for women age 30 or older in routine primary screening.52

**Guidelines available**

Based on these new developments in technology and reporting terminology, and the incorporation of HPV testing, several organizations issued guidelines.

The American Society for Colposcopy and Cervical Pathology published a consensus guideline on management of abnormal cervical cytology in 2001 and revised it in 2006.53

The American Cancer Society issued its guideline for cervical cancer screening in 2002.54

The US Preventive Services Task Force published its screening guidelines in 2003.55

The American College of Obstetricians and Gynecologists (ACOG) also made new recommendations in 2003 and updated them in December 2009.1

The following discussion highlights the consensus guidelines and the differences in the recommendations from these organizations (Table 1).56

**Start screening at age 21**

Cervical cancer screening should begin at age 21 regardless of the age of onset of vaginal intercourse, according to the 2009 ACOG guidelines.1 This represents a change from previous recommendations from ACOG, the American Cancer Society, and the US Pre-
ventive Services Task Force, which were to start screening within 3 years of the onset of vaginal intercourse.

**Rationale.** This latest recommendation is based on the high rates of clearance of HPV infection and of spontaneous dysplasia regression and the low incidence of cervical cancer in younger women.57,58 HPV infections are common in young women who have had vaginal intercourse. However, most such HPV infections are cleared by the immune system within 1 to 2 years without causing cervical dysplasia.11,12 Invasive cervical cancer in women younger than 21 years is very rare. The annual incidence is only one to two cases per 1 million women ages 15 to 19.2,55

Another reason for not screening before age 21 is that a positive test result may lead to unnecessary anxiety and potentially harmful evaluations and procedures.

**Screening intervals extended**

The 2009 ACOG guidelines lengthen the cervical cancer screening interval to every 2 years in women under age 30.1 (The 2003 ACOG guidelines said to screen every year.) For women age 30 and older, the 2009 ACOG guidelines recommend extending the interval to every 3 years when combined Pap and HPV testing are negative (changed from every 2 to 3 years).1

**Rationale.** Studies have shown little advantage in screening every year in women under the age of 30, with no higher risk of cervical cancer in women screened at a 2- to 3-year interval.59-62 The absolute risk of cervical cancer in a well-screened population is very low.63 Moreover, the absolute number of cervical cancer cases in women age 30 to 64 years screened at 3-year intervals is only four per 100,000 women.64

---

**TABLE 1**

Cervical cancer screening guidelines

<table>
<thead>
<tr>
<th>Screening Protocol</th>
<th>American Cancer Society, 200214,45</th>
<th>US Preventive Services Task Force, 200355</th>
<th>American College of Obstetricians and Gynecologists, 20033</th>
<th>American College of Obstetricians and Gynecologists, 20099</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age to begin screening</td>
<td>3 years after first vaginal intercourse or by age 21</td>
<td>3 years after first vaginal intercourse or by age 21</td>
<td>3 years after first vaginal intercourse or by age 21</td>
<td>Age 21, regardless of the age at onset of vaginal intercourse</td>
</tr>
<tr>
<td>Screening interval in women younger than age 30</td>
<td>Every year with conventional Papanicolaou (Pap) test or every 2 years using liquid test</td>
<td>Every 3 years</td>
<td>Every year</td>
<td>Every 2 years</td>
</tr>
<tr>
<td>Screening interval in women age 30 or older</td>
<td>Every 2–3 years with Pap and human papillomavirus (HPV) co-testing; if both are negative, then every 3 years</td>
<td>Every 3 years</td>
<td>Every 2–3 years with Pap and HPV co-testing; if both are negative, then every 2 years</td>
<td>Every 3 years with Pap and HPV co-testing; if both are negative, then every 3 years</td>
</tr>
<tr>
<td>Age to stop screening</td>
<td>Age 70 after three consecutive negative Pap tests in last 10 years</td>
<td>Age 65</td>
<td>No upper age limit</td>
<td>Age 65–70 after three consecutive negative Pap tests in past 10 years</td>
</tr>
<tr>
<td>Screening after hysterectomy for benign reason</td>
<td>Discontinue</td>
<td>Discontinue</td>
<td>Discontinue</td>
<td>Discontinue</td>
</tr>
</tbody>
</table>

HPV-plus-Pap testing for women over 30

Based on convincing evidence of the high sensitivity and the high negative predictive value of HPV testing, since 2003 ACOG had recommended HPV-plus-Pap testing in women over age 30. Its 2009 guidelines upgraded this recommendation to level A, ie, the highest grade, based on good and consistent scientific evidence.1 (Previously the recommendation was level B.)

The American Cancer Society also recommends combined HPV and Pap testing as the optimal screening approach in women age 30 or older, with the subsequent screening interval 3 years if both tests are negative. It also endorses Pap testing alone every 2 to 3 years as an alternative screening strategy in this age group.

The US Preventive Services Task Force recommends Pap testing every 3 years in women age 30 or older, and it does not recommend for or against HPV testing. However, neither the US Preventive Services Task Force nor the American Cancer Society has updated its guidelines in 8 years.

Rationale. Women who undergo HPV-plus-Pap testing and who test negative on both are at very low risk of developing CIN2 or CIN3 during the next 4 to 6 years. The risk is much lower than that for women who have a sole negative Pap test result.39,40 Because of this extremely high negative predictive value, women age 30 and older who had negative results on both Pap and HPV testing should be screened no more often than every 3 years.

We believe that the HPV-plus-Pap testing strategy recommended by the 2009 ACOG guidelines for women age 30 and older is the most effective screening approach. This strategy takes advantage of the high sensitivity and high negative predictive value of HPV testing, as well as the high specificity of Pap testing. It achieves almost 100% clinical sensitivity in detecting cervical dysplasia.46

When to stop screening

The 2009 ACOG guidelines for the first time call for stopping cervical cancer screening in women 65 to 70 years of age who have had three negative Pap tests in a row and no abnormal tests in the previous 10 years.1 The American Cancer Society recommends stopping screening at age 70,65 while the US Preventive Services Task Force recommends stopping at age 65.55

Rationale. Cervical cancer develops slowly, and risk factors tend to decline with age. Also, postmenopausal mucosal atrophy may predispose to false-positive Pap results, which can lead to additional procedures and unnecessary patient anxiety.66

However, it is probably reasonable to continue screening in women age 70 and older who are sexually active with multiple partners and who have a history of abnormal Pap test results.1

Women who have had a hysterectomy

According to the latest American Cancer Society, ACOG, and US Preventive Services Task Force guidelines, cervical cancer screening should be discontinued after total hysterectomy for benign indications in women who have no history of high-grade cervical intraepithelial neoplasia, ie, CIN2 or worse.1

Rationale. If the patient has no cervix, continued vaginal cytology screening is not indicated, since the incidence of primary vaginal cancer is one to two cases per 100,000 women per year, much lower than that of cervical cancer.65

However, before discontinuing screening, clinicians should verify that any Pap tests the patient had before the hysterectomy were all read as normal, that the hysterectomy specimen was normal, and that the cervix was completely removed during hysterectomy.

Be ready to explain the recommendations

It is very important for providers to understand the evidence supporting the latest guidelines, as many patients may not realize the significant technological improvements and improved understanding of the role of HPV in cervical cancer genesis that have resulted in the deferred onset of screening and the longer intervals between screenings. This knowledge gap for patients can result in anxiety when told they no longer need an annual Pap test or can start later, if the issue is not properly and thoroughly explained by a confident provider.

A FUTURE STRATEGY: HPV AS THE SOLE PRIMARY SCREENING TEST?

Since HPV testing is much more sensitive than Pap testing for detecting cervical lesions of grade CIN2 or higher, why not use HPV testing as the primary test and then do Pap
testing (which is more specific) only if the HPV test is positive?

Several major randomized clinical trials evaluated whether HPV testing could be used as the primary test. Table 2 summarizes the key conclusions from several of these trials.42,67–72

Mayrand et al46 conducted the first large randomized trial in which HPV testing was compared directly as a stand-alone test with the Pap test in a North American population with access to quality care. Results were published in 2007. In Canada, a total of 10,154 women ages 30 to 69 years in Montreal and St. John’s were randomly assigned to undergo either conventional Pap testing or HPV testing. The sensitivity of HPV testing for CIN2 or CIN3 was 94.6%, whereas the sensitivity of Pap testing was only 55.4%. The specificity was 94.1% for HPV testing and 96.8% for Pap testing. In addition, HPV screening followed by Pap triage resulted in fewer referrals for colposcopy than did either test alone (1.1% vs 2.9% with Pap testing alone or 6.1% with HPV testing alone). In other words, HPV testing was almost 40% more sensitive and only 2.7% less specific than Pap testing in detecting cervical cancer precursors.

However, more controlled trials are need-
ed to validate such a strategy. Furthermore, it remains unclear if a change from Pap testing to a primary HPV testing screening strategy will further reduce the mortality rate of cervical cancer, since the burden of cervical cancer worldwide lies in less-screened populations in low-resource settings.

Dillner et al,49 in a 2008 European study, further demonstrated that HPV testing offers better long-term (6-year) predictive value for CIN3 or worse lesions than cytology does. These findings suggest that HPV testing, with its higher sensitivity and negative predictive value and its molecular focus on cervical carcinogenesis, may safely permit longer screening intervals in a low-risk population.

Sankaranarayanan et al72 performed a randomized trial in rural India in which 131,746 women age 30 to 59 years were randomly assigned to four groups: screening by HPV testing, screening by Pap testing, screening by visual inspection with acetic acid, and counseling only (the control group). At 8 years of follow-up, the numbers of cases of cervical cancer and of cervical cancer deaths were as follows:
• With HPV testing: 127 cases, 34 deaths
• With Pap testing: 152 cases, 54 deaths
• With visual inspection: 157 cases, 56 deaths
• With counseling only: 118 cases, 64 deaths.

The authors concluded that in a low-resource setting, a single round of HPV testing was associated with a significant reduction in the number of deaths from cervical cancer. Not only did the HPV testing group have a lower incidence of cancer-related deaths, there were no cancer deaths among the women in this group who tested negative for HPV. This is the first randomized trial to suggest that using HPV testing as the sole primary cervical cancer screening test may have a benefit in terms of the mortality rate.

At present, to the best of our knowledge, there are no US data validating the role of HPV testing as a stand-alone screening test for cervical cancer.

■ HPV VACCINATION DOES NOT MEAN THE END OF SCREENING

The development of an effective HPV vaccine and FDA approval of the first quadrivalent (active against HPV 6, 11, 16, and 18) recombinant vaccine (Gardasil) in 2006 has opened a new era of cervical cancer prevention.73,74 At present, the Advisory Committee on Immunization Practices75 recommends vaccination for females 9 to 26 years old.

However, HPV vaccination will not make screening obsolete, since not all women will be vaccinated, and those who have already contracted one of these high-risk HPV types will not benefit.76,77 In addition, the current HPV vaccine does not protect against infection with other oncogenic HPV types. The experts estimate that the initial impact of the HPV vaccine on cervical cancer will not likely be apparent until at least 20 to 30 years after a nationwide vaccination program is implemented.78,79 Therefore, the HPV vaccine certainly does not portend the end of screening. Vaccination combined with continued screening will provide added benefit for cervical cancer prevention.80

The last decade has been an exciting period in the field of cervical cancer screening and prevention, with advances in technology, newly acquired knowledge, and the development of the HPV vaccine. As a result, our clinical practice has become a work in progress, continuing to evolve as we continue to discover more information. The possibility of eradicating cervical cancer has never been greater. The implementation of the most sensitive and effective screening strategy and of a worldwide HPV vaccination program will help us to eventually eradicate cervical cancer and make it a disease of the past.81


ADDRESS: Xian Wen Jin, MD, PhD, Department of Internal Medicine, G10, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail jinx@ccf.org.